Deep Value Reports

RLAY Stock Risk & Deep Value Analysis

Relay Therapeutics, Inc.

DVR Score

7.8

out of 10

Solid Pick

The Bottom Line on RLAY

We analyzed Relay Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran RLAY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 25, 2025•Run Fresh Analysis →

RLAY Deep Value Analysis

Relay possesses a unique computational drug discovery platform, Dynamo, offering a differentiated approach to precision oncology's vast TAM. Promising early clinical data for RLY-4008 and RLY-2608, strong cash ($700M+) for extensive runway, and clear catalysts ahead support significant re-rating potential. While the platform offers a competitive moat, clinical trial success remains the binary risk, pivotal for 10x growth. No major 'dud' red flags were identified, but execution risk in drug development is inherently high.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns

5-Minute Guide Thumbnail

6 Simple Steps Spotting Undervalued Stocks

Learn More
Dividend Stocks Thumbnail

Earn $500/Month with Dividend Stocks

Learn More
Swing Trading Guide Thumbnail

3 Swing Trading Strategies for Predictable Gains

Learn More